The Journal of Pediatrics
Volume 156, Issue 5 , Pages 798-803.e2, May 2010

From Regulatory Problems in Infancy to Attention-Deficit/Hyperactivity Disorder in Childhood: A Moderating Role for the Dopamine D4 Receptor Gene?

  • Katja Becker, MD

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty, Philipps University Marburg, Marburg, Germany
    • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
    • Corresponding Author InformationReprint requests: Dr Katja Becker, Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty, Philipps University Marburg, Hans-Sachs-Strasse 6, 35039 Marburg, Germany.
  • ,
  • Dorothea Blomeyer, MA

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
  • ,
  • Mahha El-Faddagh, MD

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Clinical Center Karlsruhe, Karlsruhe, Germany
  • ,
  • Guenter Esser, PhD

      Affiliations

    • Department of Clinical Psychology, Institute of Psychology, University of Potsdam, Potsdam, Germany
  • ,
  • Martin H. Schmidt, MD, PhD

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
  • ,
  • Tobias Banaschewski, MD, PhD

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
  • ,
  • Manfred Laucht, PhD

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
    • Department of Clinical Psychology, Institute of Psychology, University of Potsdam, Potsdam, Germany

Received 16 March 2009; received in revised form 3 November 2009; accepted 4 December 2009. published online 22 February 2010.

Objective

To examine whether the dopamine receptor D4 gene (DRD4) exon III VNTR moderates the risk of infants with regulatory disorders for developing attention-deficit/hyperactivity disorder (ADHD) later in childhood.

Study design

In a prospective longitudinal study of children at risk for later psychopathology, 300 participants were assessed for regulatory problems in infancy, DRD4 genotype, and ADHD symptoms and diagnoses from childhood to adolescence. To examine a potential moderating effect on ADHD measures, linear and logistic regressions were computed. Models were fit for the main effects of the DRD4 genotype (presence or absence of the 7r allele) and regulatory problems (presence or absence), with the addition of the interaction term. All models were controlled for sex, family adversity, and obstetric risk status.

Results

In children without the DRD4-7r allele, a history of regulatory problems in infancy was unrelated to later ADHD. But in children with regulatory problems in infancy, the additional presence of the DRD4-7r allele increased the risk for ADHD in childhood.

Conclusions

The DRD4 genotype seems to moderate the association between regulatory problems in infancy and later ADHD. A replication study is needed before further conclusions can be drawn, however.

ADHD, Attention-deficit/hyperactivity disorder, VNTR, Variable number of tandem repeats

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by grants from the Deutsche Forschungsgemeinschaft as part of the Special Research Program SFB 258, “Indicators and Risk Models of the Genesis and Course of Mental Disorders,” at the University of Heidelberg. The study sponsor had no input into the study design, data collection, or writing of the manuscript. K.B. is/has been involved in research/clinical trials with Eli Lilly and Shire, is on the advisory board of Eli Lilly Germany, serves on the speaker bureaus of Eli Lilly and Astra Zeneca, and has received conference attendance support from Shire. T.B. has served in an advisory or consultancy role for Lilly, Medice, Novartis, Pfizer, Shire, and UCB and has received conference attendance support or has been paid for public speaking by Lilly, Janssen McNeil, Medice, Novartis, and UCB. M.E.-F. has been paid for public speaking by Astra Zeneca and has participated in clinical trials with Eli Lilly, Novartis, and Janssen-Cilag. The other authors declare no conflicts of interest.

PII: S0022-3476(09)01228-1

doi:10.1016/j.jpeds.2009.12.005

The Journal of Pediatrics
Volume 156, Issue 5 , Pages 798-803.e2, May 2010